Capital allocation that prioritizes securing R&D funding
First written in FY2016. 5 of 7 entries say "Restated". Latest entry: FY2025.
The whole theme swung hardest in 2025: 2 of 19 companies on the "Worse" side.
31 other companies' latest entry also says "Restated".
- FY2025RestatedAnnual report
「The policy is to allocate funds to research and development expenses in the drug discovery research and pharmaceutical development fields, various expenses and research and development expenses in the cancer precision medicine business, specifically outsourcing expenses, personnel expenses, and the funding, operation, and maintenance costs of laboratories and analytical testing equipment operated as a health inspection laboratory, as well as the purchase of consumables and other items. Until specific funding needs arise, the company plans to invest the funds in highly secure financial products.」
The company continues its capital allocation policy of prioritizing the allocation of funds to research and development and analytical testing equipment and investing funds in highly secure financial products until specific funding needs arise. - FY2024-Q1SoftenedAnnual report
「and, as research and development is conducted according to the status of fundraising」
The policy on continuing research and development explicitly states that it will be carried out depending on the status of fundraising, expressing greater reliance on fundraising than previously. - FY2023-Q3RestatedAnnual report
「The Group's current policy is to maximize the potential for commercialization while keeping risk at a level that is reasonable from a management perspective, through actively entering into collaboration agreements with pharmaceutical companies and others and forming research and development partnerships. The Group will also consider raising funds as necessary.」
The company continues its capital allocation policy of prioritizing research and development and partnerships while considering fundraising as necessary. - FY2023-Q1RestatedAnnual report
「As a research and development company, the Group requires substantial research and development expenditure to expand its development pipeline for conducting clinical trials of pharmaceuticals, pursue drug discovery research actively, and undertake active initiatives in cancer precision medicine.」
The company continues to describe its business structure, in which research and development expenses precede revenue generation, as the basis for its policy of prioritizing research and development in its capital allocation. - FY2018RestatedAnnual report
「The policy is to allocate funds to research and development expenses, including joint research expenses, personnel expenses for research and development staff, and outsourcing expenses, as well as capital expenditures for the company's research and analytical testing equipment and other facilities. Until specific funding needs arise, the company plans to invest the funds in highly secure financial products.」
The company continues its policy of prioritizing the allocation of funds to research and development and analytical testing equipment and investing funds in highly secure financial products until specific funding needs arise. - FY2017RestatedAnnual report
「The policy is to allocate funds to research and development expenses, including joint research expenses, personnel expenses for research and development staff, and outsourcing expenses, as well as capital expenditures for the company's research equipment and other facilities. Until specific funding needs arise, the company plans to invest the funds in highly secure financial products.」
The company continues its capital allocation policy of prioritizing research and development funding and investing funds in highly secure financial products until specific funding needs arise. - FY2016First statedAnnual report
「For the time being, the company is retaining earnings and prioritizing the provision of funds for research and development.」
The policy is to allocate funds to joint research expenses, personnel expenses, outsourcing expenses, research equipment and other purposes, and to invest the funds in highly secure financial products until specific funding needs arise.